Besides, the addition of the Pegilodecakin (pegylated recombinant human IL-10) [160] or pegylated IFNα-2b (PEG-IFN) [161] to pembrolizumab demonstrated a manageable toxicity profile and preliminary anti-cancer activity in RCC patients mainly by provoking the CTLs anti-cancer activities. Here, IFNA1 is linked to cancer.